Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Entero Healthcare Solutions Ltd (ENTERO) is currently trading at 1,334.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Entero Healthcare Solutions Limited is an integrated, technology-enabled healthcare products distributor operating a pan‑India supply chain that distributes pharmaceuticals, medical devices, surgical consumables, OTC and nutraceuticals to retail pharmacies and hospitals, backed by a network of warehouses, proprietary platforms and an acquisitive growth strategy. The company reported strong Q3FY26 performance: consolidated revenue of Rs.1,706.5 crore (+25.6% YoY), gross margin improvement to 10.1%, EBITDA of Rs.67.8 crore (+35.5% YoY) and positive operating cash flow of Rs.49 crore driven by improved NWC and margin expansion initiatives. Entero is executing a deliberate shift into MedTech via acquisitions and partnerships; management expects MedTech annualized revenue to exceed Rs.1,000 crore and projects 70–90 bps gross margin and 50–75 bps EBITDA margin accretion on a proforma basis, indicating a material change in margin mix and long‑term profitability potential. The business combines rapid inorganic scale (51 acquisitions since inception) with a proprietary single‑interface technology platform and BI tools that provide real‑time visibility, enabling high-frequency deliveries, better secondary sales analytics and a differentiated value proposition to manufacturers and thousands of retailers. Operational scale is notable: 131 warehouses, ~622,821 sq ft aggregate area, ~89,200 SKUs, relationships with 3,100+ manufacturers and service to ~97,600 retail pharmacies—assets that create a defensible distribution moat and facilitate cross-sell, private label and pan‑India distribution agreements.
Over the past 52 weeks, Entero Healthcare Solutions Ltd has traded between a low of ₹944.00 and a high of ₹1,509.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Entero Healthcare Solutions Ltd has a market capitalization of approximately 5,891.60. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Entero Healthcare Solutions Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 52.27 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 5,891.60 Cr, Entero Healthcare Solutions Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Entero Healthcare Solutions Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Entero Healthcare Solutions Ltd is 52.27. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stock
Entero Healthcare Solutions Limited is an integrated, technology-enabled healthcare products distributor operating a pan‑India supply chain that distributes pharmaceuticals, medical devices, surgical consumables, OTC and nutraceuticals to retail pharmacies and hospitals, backed by a network of warehouses, proprietary platforms and an acquisitive growth strategy.
The company reported strong Q3FY26 performance: consolidated revenue of Rs.1,706.5 crore (+25.6% YoY), gross margin improvement to 10.1%, EBITDA of Rs.67.8 crore (+35.5% YoY) and positive operating cash flow of Rs.49 crore driven by improved NWC and margin expansion initiatives.
Entero is executing a deliberate shift into MedTech via acquisitions and partnerships; management expects MedTech annualized revenue to exceed Rs.1,000 crore and projects 70–90 bps gross margin and 50–75 bps EBITDA margin accretion on a proforma basis, indicating a material change in margin mix and long‑term profitability potential.
The business combines rapid inorganic scale (51 acquisitions since inception) with a proprietary single‑interface technology platform and BI tools that provide real‑time visibility, enabling high-frequency deliveries, better secondary sales analytics and a differentiated value proposition to manufacturers and thousands of retailers.
Operational scale is notable: 131 warehouses, ~622,821 sq ft aggregate area, ~89,200 SKUs, relationships with 3,100+ manufacturers and service to ~97,600 retail pharmacies—assets that create a defensible distribution moat and facilitate cross-sell, private label and pan‑India distribution agreements.
Retailing
Pharmacy Retail
5,808 Cr
Low Risk
51.5
75.0
1.0
3.3
1,509.90
944.00
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
7
Neutral
4
Bullish
3
Bearish
8
Neutral
4
Bullish
34
Bearish
1
Neutral
0
Bullish
31
Investor Presentation
Investor presentation filed under Reg 30 with audited Q4 & FY26 results: FY26 like‑for‑like revenue +31.5% YoY, EBITDA margin 4.0% (Q4 4.5%), operating cashflow INR 96.2 Cr, positive ROCE/ROE and seven acquisitions including MedTech.
Earnings Presentation
Entero released its Q4 & FY26 investor presentation: FY26 LFL revenue +31.5% (reported +29.3%), EBITDA margin 4.0% (Q4 4.5%), operating cashflow INR 96.2 Cr, ROCE 14.6%, and seven acquisitions (incl. Anand Chemiceutics).
Board Meeting Outcome
Board meeting on 25-May-2026: approved audited standalone & consolidated FY26 results (unmodified opinion), re‑appointed auditors and independent directors, allotted 7,240 equity shares on ESOP exercise, granted 7,300 fresh ESOPs, set AGM for 19-Aug-2026 and approved a slump‑sale acquisition.
Board meeting outcome
Board approved audited standalone & consolidated FY26 results (unmodified), re‑appointed three independent directors, re‑appointed EY as internal auditor, approved allotment of 7,240 shares on ESOP exercise and grant of 7,300 ESOs; AGM on Aug 19, 2026; approved slump‑sale acquisition.
Board Meeting Outcome
Board approved audited standalone and consolidated results for quarter/year ended Mar 31, 2026; re‑appointed Ernst & Young LLP as internal auditor for FY2026‑27; approved re‑appointment of three independent directors, ESOP allotment/grant, acquisition via slump sale and AGM on Aug 19, 2026.
Board Meeting Outcome
Board approved audited standalone and consolidated results for quarter and year ended Mar 31, 2026; re‑appointed three Non‑Executive Independent Directors for second five‑year term (subject to shareholder approval); approved ESOP allotments/grants, AGM date and a subsidiary's acquisition via slump sale.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
536.00 | 6,919 Cr | 59.17 | 10.05 | 0.23 | 16.98 | 15.52 | 7.95 | ||
461.70 | 6,217 Cr | 50.72 | 6.38 | 0.36 | 12.99 | 18.06 | 4.36 | ||
1316.00 | 5,892 Cr | 52.27 | 3.33 | 0.00 | 6.26 | 9.07 | 4.63 | ||
656.05 | 5,235 Cr | 42.22 | 5.50 | 0.00 | 13.04 | 11.94 | 4.46 | ||
34.92 | 4,834 Cr | -11.76 | 4.62 | 0.00 | -40.63 | -16.68 | -12.64 | ||
116.60 | 4,486 Cr | 41.87 | 2.85 | 0.00 | 6.59 | 8.20 | 2.82 | ||
526.05 | 4,473 Cr | 12.32 | 1.11 | 0.00 | 3.58 | 4.67 | 7.47 | ||
| Median: 7 Co. | — | 526.05 | 5,235 Cr | 42.22 | 4.62 | 0.00 | 6.59 | 9.07 | 4.46 |
